🔴 Outlook Therapeutics is trading 5.3% down today on profit-taking after a multi-day post-FDA approval rally

Outlook Therapeutics is trading 5.3% down at $0.98 as the stock enters a period of consolidation following a significant multi-day rebound.

• The pullback follows strong momentum earlier this week, including gains of 10.6% on July 29 and 4.0% on July 30.
• The recent rally was driven by the FDA approval of LYTENAVA for the treatment of wet AMD, alongside reports of insider buying.
• There are no fresh company filings or headlines this morning, suggesting today's move is a reaction to overextended gains rather than new fundamental developments.